Final Analysis of the GEM-BELA-VRd Phase II Trial: Belantamab Mafodotin Plus VRd in Newly Diagnosed Transplant-Eligible Myeloma After 2 Years of Maintenance with Belantamab and Lenalidomide

IF 2.7 4区医学 Q2 HEMATOLOGY

Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2025-09-01 DOI:10.1016/S2152-2650(25)03452-4

Verónica González-Calle, Noemi Puig, Enrique Ocio, Javier de la Rubia, Paula Rodríguez-Otero, Borja Puertas, Felipe de Arriba, Valentin Cabañas, Esther Gonzalez Garcia, Cristina Encinas, Alexia Suarez-Cabrera, Joan Bargay, Joaquin Martinez-Lopez, Sonia González-Pérez, Jose Angel Hernandez Rivas, Laura Rosiñol, Beatriz Rey Búa, Miguel Teodoro Hernandez, Rafael Alonso Fernandez, Bruno Paiva, María-Victoria Mateos

引用次数: 0

查看原文本刊更多论文

GEM-BELA-VRd II期试验的最终分析：贝兰他单抗和来那度胺维持2年后，贝兰他单抗+ VRd治疗新诊断的适合移植的骨髓瘤

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Lymphoma, Myeloma & Leukemia ONCOLOGY-HEMATOLOGY

CiteScore

2.70

自引率

3.70%

发文量

1606

审稿时长

26 days

期刊介绍： Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.